Fed. Circ. Affirms No Block On Amgen's Eye Med Biosimilar

By Theresa Schliep · March 14, 2025, 6:52 PM EDT

The Federal Circuit on Friday agreed with a lower court decision declining to temporarily block Amgen's biosimilar of Regeneron's blockbuster eye medication Eylea, affirming that court's application of claim construction precedent...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.

Case Number

24-2351

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

September 24, 2024